We would love to hear your thoughts about our site and services, please take our survey here.
Continuing to head in the right direction here.
More good news with further validation of Cordel's offering,
Nice rise to 52 week high territory. H1 update in the next few weeks.
Very welcome on top of the already decent dividend yield.
Now they are the kind of results you want to wake up to. Bought a few more yesterday hoping for decent results and not disappointed to say the least. A great UK company with a world leading patent protected IP across several sectors and still with masses of cash for future investment etc.
Thank-you for this Claire. Much appreciated.
UK defence firm Qinetiq says that surging demand for electric tanks will drive a boost in sales, as armed forces rush to build next-generation fighting vehicles.
The appetite for electric drivetrains for the tanks, cyber security products and a range of sophisticated practice targets, used to train military personnel to learn how to shoot down aircraft, will also grow, said Steve Wadey, the company’s chief executive.
He added that armed forces around the world were spending more to keep their skills sharp in the wake of Russia’s attack on Ukraine.
Qinetiq is working alongside US defence firm Oshkosh and BAE Systems in the UK to provide components for the next generation of electric armoured transports.
“We're leveraging our electrification technology from the UK into that US programme. We expect that to be a significant contributor going forward,” Mr Wadey said.
The contractor also expects militaries around the world to buy more of its targets, which mimic warplanes and ships so that troops, sailors, and air crews can hone their skills in taking them down.
"You actually present them with these targets as different ways of simulating a real threat. And therefore, government customers are our customers for that, because they need to train, they need to test and be ready operationally,” Mr Wadey added.
Qinetiq said it remained on the lookout for rivals it can buy to bolster its six main businesses of experimentation and technology, robotics and autonomous systems, engineering services and support, test and evaluation, cyber and information, and training and mission rehearsal.
Consumer Focus
In the UK it has most of these well covered, suggesting it is likely to make more purchases in its other main markets of the US and Australia.
A UK defence contractor acquiring foreign competitors would buck a recent trend after many British arms makers have been snapped up, largely by American buyers who have taken advantage of a weak pound.
Submarine systems developer Ultra and aircraft parts maker Meggitt have recently been sold to overseas companies.
Qinetiq said orders for the financial year increased 41pc to £1.7bn and sales rose 20pc to £1.58bn. Profit after tax rose to £153m from £118m.
Schlum, I think the "super bonus" is based on a price of 62.4p. Details as per the below Grant of Options RNS:
RNS Number : 5322X. Circassia Pharmaceuticals Plc. 19 December 2019
Grant of options
Oxford, UK - 19 December 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted nil-cost options ("Options") today over 4,322,767 ordinary shares in the Company ("Ordinary Shares") to Ian Johnson, who was appointed as Executive Chairman of the Company on 5 December 2019, under the 2019 Performance Share Plan.
The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p, equating to three times the average closing price for an Ordinary Share for the 10 dealing days immediately preceding the grant date, for at least 30 consecutive dealing days or a liquidity event occurring above this level.
Should some or all of the Options be exercised, the Ordinary Shares will be purchased on the open market by The Circassia Pharmaceuticals plc Employee Benefit Trust on behalf of Mr Johnson.
Top quality post GLTader
Rivaldo,
I recalled seeing this before and found a post from you in September 2021 as follows: (since then Berenberg have raised their target SP for CAPD to 127p of course)
"Here's kaizenkid's summary FYI:
"Berenberg have published a note on CAPD, focused on MSA Labs: Here are a few snippets:
Believe $50m of MSA revenue possibly by 2026, believe CAPD can be $250m revenue biz, peers to MSA like ALS have 34% EBITDA margins, the Chrysos technology revolutionises the testing process - an hour from start to finish vs. 1 day, low cost and more environmentally friendly, revised impact from MSA labs assumptions leads to 10% increase to revenues, 17% increase to EBITDA and 20% rise in EPS (all based on 2022 to 2026), price target 113. 7.2x PE their 2022 forecasts.""
$50 million annually that is
Yes. Impressive work by Leo and you in your precis.
MSALABS: Stephen English mentioned it in the Q&A (at around 1hr 05mins in) that Berenberg are predicting MSALABS to be a $50million business by 2026 and stick a six times multiple on that and we'd all be very happy.
Excellent presentation by Sam and Gareth on Investor Meet Company this morning. The recording of this will be on InvestorMeetConpany's site later if anyone wants a look.
Good to get the placing out of the way with some solid backers at a price I think is reasonable and which, hopefully sets a lower boundary for the SP.
Small top up this morning and looking forward to EISB's journey from here. A ways to go but definitely looking positive IMHO
Superb update. May the SP rise continue. Holding long term here and it will be interesting to follow the story and see if the much talked about buy out by a big player happens.
I notice EISB has made it onto Zac's list of stock tips for 2022 and EISB has moved up to the 2nd most followed company on V O X Markets.
"9. East Imperial (EISB): 10p Target 25p
To say a company is going to be “the next” this or that is normally a punchy thing to say. However, in the case of premium beverages group East Imperial, this looks as though it is more than merited. It came to market in July with a market cap of £30m, which compares to Fevertree (FEVR), the premium drink mixers giant at £3bn. The latter made its way to being a giant killer in the space, largely through the genius of its distribution. What could be the big win for East Imperial is to go one step ahead of Fevertree, and really crack the American market, and this is what bulls of the shares are backing it to do. What has been interesting is that since listing in July we have gone through a requisition, something which beefed up the board. The new management experience which is blue chip via New Look and M&S, now puts everything in place for the company to achieve a rollout as good or better than Fevertree has achieved. At the current modest market cap, the market has not factored in more than a fraction of the group’s potential."